What are ASCO/OH(CCO) recommendations for second-line therapy for stage IV non–small cell lung cancer (NSCLC) in patients with sensitizing endothelial growth factor receptor (EGFR) mutation?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Second-line therapy:

  • In patients who did not receive osimertinib and who have an  EGFR T790M mutation at the time of progressive disease, osimertinib should be offered.

In patients with any other EGFR mutation whose disease has progressed on EGFR TKIs, or those whose disease has progressed on osimertinib, treatment based on NSCLC without driver mutations may be offered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!